Umbilical Cord-derived Mesenchymal Stem Cell Infusion for Treating ACLF

NCT06884904 | Not Yet Recruiting Phase 2

• 1 other identifier: MSCTACLF-02
• Study Type: interventional
• Target: 96
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is a multicenter, randomized, double-blind, placebo-controlled adaptive design Phase IIb/III clinical trial. It employs a seamless adaptive design, divided into Phase IIb and Phase III, focusing on patients with acute-on-chronic liver failure (ACLF). Eligible patients meeting the inclusion criteria and not disqualified were randomized in a 2:2:1:1 ratio during Phase IIb to receive either a high-dose experimental group (4.0×10\^6/kg of injectable mesenchymal stem cells derived from umbilical cord), a low-dose group (2.0×10\^6/kg), a high-dose placebo control group (with equivalent volume of solvent calculated at 4.0×10\^6/kg), or a low-dose placebo control group (with equivalent volume of solvent calculated at 2.0×10\^6/kg). In Phase III, patients were randomized in a 1:1 ratio to the experimental group (injectable umbilical cord-derived mesenchymal stem cells) or the control group. All groups received standard treatment alongside either the experimental drug (experimental group) or placebo (control group) to evaluate and confirm the efficacy and safety of injectable umbilical cord-derived mesenchymal stem cells in treating acute-on-chronic liver failure.

Conditions

Acute-On-Chronic Liver Failure

Keywords

acute-on-chronic liver failure; mesenchymal stem cells

Outcome Measures

Primary Outcomes (1)

• mortality rate

  90 day mortality rate (D90) of subjects randomly assigned and receiving the investigational drug

  90 day

Study Arms (4)

Low-dose experimental group

EXPERIMENTAL

2.0×10\^6/kg

Drug: Low-dose experimental group

High-dose experimental group

EXPERIMENTAL

4.0×10\^6/kg

Drug: High-dose experimental group

Low-dose placebo control group

PLACEBO COMPARATOR

Equivalent volume of solvent calculated at 2.0×10\^6/kg

Drug: Low-dose placebo control group

High-dose placebo control group

PLACEBO COMPARATOR

Equivalent volume of solvent calculated at 4.0×10\^6/kg

Drug: High-dose placebo control group

Interventions

Low-dose experimental group DRUG

2.0\*10\^6/kg

Low-dose experimental group

High-dose experimental group DRUG

4.0\*10\^6/kg

High-dose experimental group

Low-dose placebo control group DRUG

Equivalent volume of solvent calculated at 2.0×10\^6/kg

Low-dose placebo control group

High-dose placebo control group DRUG

Equivalent volume of solvent calculated at 4.0×10\^6/kg

High-dose placebo control group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age between 18 and 70 years (inclusive) at the time of signing the informed consent form, regardless of gender.
• Patients with hepatitis B virus (HBV)-associated acute-on-chronic liver failure (ACLF) meeting the following criteria: Total bilirubin (TBil) ≥12 mg/dL (equivalent to 205 μmol/L); International normalized ratio (INR) ≥1.5 or prothrombin activity (PTA) ≤40%;
• All participants and their partners agree to use effective non-pharmacological contraception during the trial and for 6 months after trial completion, with no plans for conception during this period.
• Voluntarily participate in the clinical study and sign the informed consent form.

You may not qualify if:

• History of allergy to any component of the investigational drug or bovine-derived products.
• Acute, subacute, or chronic liver failure unrelated to HBV, or ACLF caused by: Concurrent hepatitis A, C, or E virus infection; Autoimmune liver disease; Biliary obstruction.
• Presence of any of the following complications: \<1\> Active gastrointestinal bleeding (e.g., hematemesis and/or melena) or high- risk esophageal/gastric varices (confirmed by endoscopy or imaging within 3 months prior to screening). \<2\> Imaging evidence (ultrasound or CT) of cavernous transformation of the portal vein or portal vein occlusion. \<3\> History of transjugular intrahepatic portosystemic shunt (TIPS). \<4\> Grade 3 or 4 hepatic encephalopathy. \<5\> Serum creatinine ≥2 mg/dL. \<6\> Respiratory insufficiency (e.g., dyspnea, cyanosis) with peripheral oxygen saturation ≤93% at rest.
• Severe underlying diseases, including: \<1\>Septic shock (requiring vasopressors to maintain mean arterial pressure ≥65 mmHg despite adequate fluid resuscitation, with blood lactate \>2 mmol/L). \<2\> Uncontrolled cardiac conditions: Myocardial ischemia or infarction (CTCAE v5.0 Grade ≥II), Arrhythmias requiring intervention, NYHA Class III-IV heart failure. \<3\> Active malignancy (solid or hematologic). \<4\> Diagnosed pulmonary hypertension or suspected pulmonary embolism. \<5\> IgA deficiency, Henoch-Schönlein purpura, hemophilia, or idiopathic thrombocytopenia. \<6\> Immunodeficiency disorders (e.g., HIV infection, congenital/acquired immune deficiency).
• Current systemic corticosteroid therapy for other diseases.
• Psychiatric or other conditions deemed by the investigator to interfere with study assessments.
• Planned or active registration for liver transplantation, or anticipated transplantation within 3 months.
• History of liver transplantation.
• Alcohol or substance abuse: Chronic alcohol use (\>5 years with ethanol intake ≥40 g/day for males or ≥20 g/day for females), Heavy alcohol use (\>80 g/day ethanol) within 2 weeks prior to screening, Abstinence \<6 months.
• Participation in another clinical trial within 3 months prior to screening (excluding screen failures or withdrawal before dosing).
• Pregnancy, lactation, or positive pregnancy test at screening.
• Any other condition that, in the investigator's judgment, may confound study results, pose risks, or compromise the participant's best interests.

Sponsors & Collaborators

• National Engineering Center of Cell Products: lead

MeSH Terms

Conditions

Acute-On-Chronic Liver Failure

Condition Hierarchy (Ancestors)

Liver Failure, Acute; Liver Failure; Hepatic Insufficiency; Liver Diseases; Digestive System Diseases

Central Study Contacts

Zhibo Han

CONTACT

+86-02266211430; hanzhibo@amcellgene.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 13, 2025
• First Posted: March 19, 2025
• Study Start: April 15, 2025
• Primary Completion (Estimated): April 14, 2027
• Study Completion (Estimated): April 14, 2028
• Last Updated: March 19, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share